https://www.bioworld.com/rss en-us Researchers from Rivus Pharmaceuticals Inc. presented preclinical efficacy data on RV‑202, a novel oral mitochondrial uncoupler with activity attributed to adenine nucleotide translocase (ANT) activation, in models of obesity. http://www.bioworld.com/articles/732015 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732015-ant-activating-uncoupler-rv-202-drives-selective-fat-loss-in-obese-mice Obesity, fat cell research concept image Although GLP-1 receptor agonists (GLP-1RAs) have significantly advanced obesity treatment, their limitations underscore the need for new therapies that promote weight loss while preserving muscle and supporting metabolic health. Researchers from Rivus Pharmaceuticals Inc. discussed the discovery and preclinical profile of RV-8451, a potentially first-in-class, oral, nonpeptide GLP-1RA. http://www.bioworld.com/articles/731995 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731995-rivus-glp-1ra-leads-to-fat-selective-weight-loss-with-lean-mass-preservation Woman measuring her body fat with caliper IBI-3032 is a nonpeptide GLP-1 receptor agonist under development at Innovent Biologics Co. Ltd. for the potential treatment of obesity and other metabolic diseases. The company recently reported results of preclinical studies in which pharmacokinetic profiling was performed in vivo in different species, and the candidate’s in vivo efficacy was tested in a murine model with diet-induced obesity. http://www.bioworld.com/articles/731939 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731939-innovents-ibi-3032-reduces-body-weight-in-preclinical-obesity Oral medication Researchers from Innovent Biologics (Suzhou) Co. Ltd. presented preclinical efficacy data on IBI-3040, a dual agonist of amylin and calcitonin receptors (CTR). In vitro studies in UM-UC-3 cells expressing human CTR and amylin receptor subtypes AMY-1 and AMY-3 showed that IBI-3040 elicited robust receptor activation, as evidenced by cAMP accumulation assays. http://www.bioworld.com/articles/731937 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731937-next-gen-amylin-ibi-3040-drives-potent-weight-loss-in-preclinical-studies Drug R&D concept image. Clinical evidence supports the integration of dual amylin and calcitonin receptor agonism (DACRA) with GLP-1, GIP and glucagon receptor signaling (triple G) as a synergistic approach for appetite modulation, insulin sensitivity and weight loss. Oban Biopharma Inc. is developing OBT-676, an oral small molecule that delivers full DACRA activity with triple G partial agonism for the treatment of metabolic disorders. http://www.bioworld.com/articles/731936 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731936-oban-bios-obt-676-shows-promising-results-for-obesity Tape measure wrapped around scale INHBE encodes the hepatokine activin E, a key mediator of liver-adipose crosstalk involved in the regulation of lipid metabolism and energy balance. Researchers from Innovent Biologics Co. Ltd. recently released preclinical efficacy data on IBI-3046, a novel RNAi therapeutic targeting INHBE. http://www.bioworld.com/articles/731933 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731933-inhbe-rnai-drives-sustained-metabolic-benefits Glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling regulates key metabolic processes, including postprandial insulin secretion, appetite control, lipid storage and overall energy balance. Researchers from Antag Therapeutics Aps presented preclinical efficacy data on the combination of AT-7687, a GIPR antagonist, and cagrilintide in obese insulin-resistant monkeys. http://www.bioworld.com/articles/731855 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731855-antags-gipr-antagonist-shows-promise-in-obesity-and-cardiometabolic-disease Illustration of glucose molecules in a bloodstream Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an editorial published in its flagship journal Diabetes Care at the ADA’s meeting in New Orleans last Friday. Diabetes Care at the ADA’s meeting in New Orleans last Friday.]]> http://www.bioworld.com/articles/731872 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731872-researchers-hit-back-after-colleagues-removed-from-ada-meeting Hands holding paper Glucagon-like peptide 1 receptor agonist (GLP-1RA) compounds have become game changers in the treatment of obesity, but they have limitations due to long-term efficacy, lean mass preservation and tolerability in certain populations. Mitorx Therapeutics Ltd. has presented data for MTRX-31 (Myo-004), a mitochondrial-targeted compound that provides an alternative mode of action for treating obesity. http://www.bioworld.com/articles/731840 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731840-mtrx-31-restores-mitochondrial-metabolism-in-obesity Art concept for metabolism Researchers from Verdiva Bio Ltd. and collaborators recently presented preclinical data on VRB-103, an oral amylin analogue, comparing its profile with those of cagrilintide and eloralintide, two subcutaneously administered analogues currently in clinical development. http://www.bioworld.com/articles/731839 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731839-vrb-103-shows-potent-and-selective-amylin-receptor-activity Beta cells β cell. Credit: Melton laboratory, Harvard University Researchers from Ractigen Therapeutics Co. Ltd. presented preclinical data on LiCO-saUcp1, a small activating RNA (saRNA) therapeutic designed to upregulate UCP1 expression in adipose tissue. http://www.bioworld.com/articles/731837 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731837-ractigens-sarna-therapy-delivers-sustained-fat-loss-while-preserving-muscle Illustration of adipose tissue under the skin Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an editorial published in its flagship journal Diabetes Care at the ADA’s meeting in New Orleans last Friday. Diabetes Care at the ADA’s meeting in New Orleans last Friday.]]> http://www.bioworld.com/articles/731723 Wed, 10 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731723-researchers-hit-back-after-colleagues-removed-from-ada-meeting Hands holding paper Dexcom Inc. and Insulet Corp. reported new clinical trial data on their diabetes technologies at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, offering insights that could aid in clinical adoption. Abbott Laboratories, meanwhile, highlighted the risks of diabetic ketoacidosis (DKA) and presented data showing the growing challenge of identifying DKA as it can develop quickly and mimic common illnesses. http://www.bioworld.com/articles/731707 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731707-pumps-patches-and-fixes-at-the-ada Dexcom G7 CGM Dexcom Inc.’s G7 continuous glucose monitoring system. GLP-1 receptor agonists remained center stage at the 2026 Scientific Sessions of the American Diabetes Association with Boehringer Ingelheim GmbH and Astrazeneca plc, joining the leaders, Eli Lilly and Co. and Novo Nordisk A/S, in presenting data for their respective GLP-1 drugs. http://www.bioworld.com/articles/731706 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731706-glp-1s-and-more-weigh-in-at-ada Close-up of injector pen in hands At the recent American Diabetes Association meeting, researchers from Century Therapeutics Inc. presented preclinical efficacy data on CNTY-813, an induced pluripotent stem cell (iPSC)-derived cell therapy engineered using the company’s proprietary Allo-Evasion 5.0 platform. http://www.bioworld.com/articles/731758 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731758-cnty-813-enables-durable-glucose-control-without-immunosuppression-need Illustration of pancreas, close up of islet Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that has limited available therapies. Shanghai Minwei Biotechnology Co. Ltd. has developed and presented data for MWN-105, a GLP-1/GIP/FGF21 triple agonist aimed at controlling metabolic dysfunction and fibrosis during MASH. http://www.bioworld.com/articles/721996 Wed, 09 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/721996-mwn-105-ameliorates-mash-symptoms-in-the-preclinical-setting Liver over digital lens background Insparin is a protein isolated from human adenovirus Ad36 that induces cellular glucose uptake without impacting safety. A preclinical study of insparin looked at its potential antidiabetic effects compared to those of pioglitazone. http://www.bioworld.com/articles/721758 Fri, 04 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/721758-insparin-a-promising-antidiabetic-peptide Peptide illustration Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an agonist of thyroid hormone receptor β (THR-β) and its metabolic impact on preclinical models of obesity in combination with semaglutide was investigated. http://www.bioworld.com/articles/721743 Thu, 03 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/721743-eccogenes-ecc-4703-leads-to-greater-weight-loss-in-preclinical-studies Pills, bottle, scale and-measuring tape ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in healthy subjects and in patients with obesity, respectively. http://www.bioworld.com/articles/721725 Wed, 02 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/721725-asc-47-shows-superior-weight-loss-effect-compared-to-semaglutide Woman measuring her body fat with caliper Therapies based on glucagon-like peptide 1 (GLP-1) are the most effective for treating obesity to date, but their efficacy and tolerability are limited by gastrointestinal side effects and compensatory reduction of energy expenditure. http://www.bioworld.com/articles/721662 Tue, 01 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/721662-bi-4659-reverses-diet-induced-obesity-in-mice Man measuring waist Synthetic mitochondrial protonophores uncouple ATP production, increasing tricarboxylic acid (TCA) cycle activity and fat oxidation to meet energy demands. This approach promotes weight loss and may also enhance glycemic control and lipid metabolism. http://www.bioworld.com/articles/721660 Tue, 01 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/721660-tlc-1180-supports-durable-weight-loss-and-metabolic-gains-in-combination-approaches Light micrograph and 3D illustration of adipose tissue. MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials. http://www.bioworld.com/articles/721595 Mon, 30 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/721595-preclinical-characterization-of-antiobesity-drug-met-097 Doctor measuring patient's waist The main feature of type 1 diabetes is the destruction of pancreatic β cells that produce insulin. Immunotherapy directed at inhibiting immune interactions between cytokines and islet cells and preserving its functioning is key to reverse the progression of the disease. http://www.bioworld.com/articles/721578 Fri, 27 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/721578-ob-756-shows-therapeutic-efficacy-in-type-1-diabetes IBI-3030 from Innovent Biologics Inc. is a novel antibody-peptide conjugate targeting PCSK9 that shows agonism for GLP-1R, GCGR and GIPR, aimed to confer therapeutic benefit against cardiovascular disease. http://www.bioworld.com/articles/721577 Fri, 27 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/721577-ibi-3030-protects-against-cardiovascular-risk-in-mice Heart with blocked arteries Amylin is an attractive target in the management of obesity, since it is a peptide hormone co-secreted with insulin in response to food intake, and suppresses appetite and delays gastric emptying. At the American Diabetes Association's Scientific Sessions in Chicago, Structure Therapeutics Inc. presented data regarding the dual amylin receptor and calcitonin receptor agonist ACCG-2671 for obesity treatment. http://www.bioworld.com/articles/721545 Thu, 26 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/721545-accg-2671-reduces-body-weight-in-dio-rats Abbott Laboratories grabbed attention in early June with its announcement of a partnership with Tandem Diabetes Care Inc. to develop a multianalyte sensor for people with diabetes that would measure ketones as well as glucose. http://www.bioworld.com/articles/721229 Wed, 25 Jun 2025 12:00:00 -0400 https://www.bioworld.com/articles/721229-multiple-multianalyte-sensors-for-diabetes-on-horizon Abbott sign Credit: Abbott Laboratories With a growing number of people wearing continuous glucose monitors and an ever-shrinking number of hospital-based nurses, bringing your own device or using personal CGMs to measure glucose levels during hospitalizations seems like a no-brainer. http://www.bioworld.com/articles/721227 Wed, 25 Jun 2025 12:00:00 -0400 https://www.bioworld.com/articles/721227-in-patient-byod-still-troublesome-for-cgm-makers Product image G6 CGM system. Credit: Dexcom Inc. Classically, the diagnosis of type 1 diabetes comes after a patient presents with unexplained weight loss, extreme thirst and frequent urination and a lab test reveals off-the-charts blood glucose levels. At the 85th Scientific Sessions of the American Diabetes Association in Chicago, researchers highlighted two options – a blood test and a machine learning model – for diagnosing the disease much earlier in its progression, when damage to the pancreas' beta cells could be slowed. http://www.bioworld.com/articles/721219 Tue, 24 Jun 2025 12:00:00 -0400 https://www.bioworld.com/articles/721219-two-new-options-presented-at-ada-for-early-diagnosis-of-t1d Blood glucose chart and monitor, stethoscope, injector pen At the American Diabetes Association 85th Scientific Sessions in Chicago June 20-23, Fractyl Health Inc. presented results from two studies evaluating very different approaches to treating – and possibly curing – type 2 diabetes. http://www.bioworld.com/articles/721208 Mon, 23 Jun 2025 12:00:00 -0400 https://www.bioworld.com/articles/721208-fractyl-pursues-dual-track-to-cure-t2-diabetes Illustration of Revita DMR in intestine Revita duodenal mucosal resurfacing system. Credit: Fractyl Laboratories Inc. Large-scale human genetic studies have revealed that loss-of-function INHBE variants are associated with a lower abdominal to gluteofemoral fat ratio, improved metabolic profile, and reduced fasting glucose levels. http://www.bioworld.com/articles/710165 Mon, 08 Jul 2024 09:00:00 -0400 https://www.bioworld.com/articles/710165-liver-targeted-sirna-improves-body-composition-in-mouse-models Liver illustration